Who founded Coultreon?

Coultreon was founded by Pierre Raboisson, Marie De Vulder, Guy Peeters, John-Paul Gallivan, Fabrice Kolb, Pieter Peeters, François Gonzalvez, Sandrine Vendeville, Joost Kolkman in 2025.

Who are Coultreon's investors?

Coultreon's investors include Finchley Healthcare Ventures, Longwood Fund, Luma Group, Sofinnova Ventures, BAM Elevate, Forbion, Novo Holdings, Regeneron Ventures and 1 more.

How much funding has Coultreon raised?

Coultreon has disclosed $125M raised across 1 round.

Coultreon

Founded 2025 · 32 employees on LinkedIn · 10 known investors

Find your way into Coultreon

Paths you didn't know you had: your email and LinkedIn already hold routes to the Coultreon team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.

AI & Machine Learning Biotech

Founders & leadership

Pierre Raboisson Chief Executive Officer Chief Scientific Officer Co-founderPierre Raboisson is a pharmacist and Ph.D. holder with over 25 years in biopharmaceutical development; he founded Coultreon and previously led drug discovery efforts contributing to multiple approved therapeutics including Simeprevir, and built R&D organizations across Europe and the United States.

Marie De Vulder Chief Legal Officer Co-founderShe holds an Advanced Master's degree in Intellectual Property Rights and ICT Law from the University of Leuven and has background in corporate law and contract negotiation.

Guy Peeters Chief Financial Officer Co-founderHe brings over 20 years of finance leadership experience in biotech and pharmaceuticals, including roles as SVP of Finance, Procurement & Facilities at Galapagos, Senior Finance Director at Janssen Germany, and 15 years in finance positions at Johnson & Johnson; he holds a Master's degree in Applied Economics from the University of Antwerp and a degree in International Taxation from KU Leuven.

John-Paul Gallivan Head of Development Co-founderHead of Development and co-founder of Coultreon. Gallivan has held roles in both small biotech and large pharmaceutical companies, with experience in drug development and commercialization across oncology and virology programs.

Fabrice Kolb Head of Immunology Co-founderHe brings over two decades of drug discovery experience from roles at Galapagos (2019–2025), Roche (2015–2019), and Novartis (2006–2015), where he led immunology and oncology programs and contributed to the development of multiple approved therapeutics including complement-targeted antibodies and inhibitors.

Pieter PeetersOperating & Technology Officer Co-founder

François Gonzalvez Co-founderHe brings two decades of experience in oncology and immuno-oncology drug discovery, including leading programs from target identification through phase 1 development.

Sandrine Vendeville Co-founderShe previously co-invented Simeprevir, an approved HCV treatment, and led development of multiple clinical-stage therapeutic candidates including an HCV nucleoside inhibitor, an RSV fusion inhibitor, and an HBV capsid assembly modulator. She has expertise in medicinal chemistry, drug metabolism, and intellectual property strategy, with over 50 patents and publications.

Joost Kolkman Co-founderJoost Kolkman has over 20 years of experience in drug discovery and development, including team leadership, collaboration with academic institutions and contract research organizations, and technical assessment of biotech platforms and assets. He co-founded Coultreon to advance small and large molecule therapeutic programs across multiple disease areas.

Investors · 10

Finchley Healthcare Ventureslisted by Finchley Healthcare VenturesMontreal

How we know: Finchley Healthcare Ventures's portfolio page · coultreon.com · Not right? Tell us

Longwood Fundlisted by Longwood FundBoston

How we know: Longwood Fund's portfolio page · coultreon.com · open dataset · 5k.vc investor directory · Not right? Tell us

Luma Grouplisted by Luma GroupNew York

How we know: Luma Group's portfolio page · coultreon.com · Not right? Tell us

Sofinnova Ventureslisted by Sofinnova VenturesMenlo Park · $100K – $15M

How we know: Sofinnova Ventures's portfolio page · a partner's Signal profile · coultreon.com · Not right? Tell us

BAM ElevatereportedChicago

How we know: coultreon.com · Not right? Tell us

ForbionreportedNaarden

How we know: funding news · coultreon.com · open dataset · 5k.vc investor directory · Not right? Tell us

Novo HoldingsreportedCopenhagen · $1.1M – $54M

How we know: funding news · coultreon.com · Not right? Tell us

Regeneron Venturesreported

How we know: coultreon.com · Not right? Tell us

Samsara BioCapitalreportedMenlo Park

How we know: coultreon.com · Not right? Tell us

Also in the syndicate · 1

Galapagos

Funding

SEC filings, press & company announcements

$125M disclosed across 1 round · 2026

$125MSeries AApr 2026 · 3 sources
Sofinnova Investments (lead), Balyasny Asset Management, Finchley Healthcare Ventures, Forbion, Galapagos, Longwood Fund, Luma Group, Novo Holdings, Regeneron Ventures, Samsara BioCapital
Source ↗

Source: company announcements and press reports — follow each round's link for the claim.

Related companies · 2

BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Day One BiopharmaceuticalsDay One is a biopharmaceutical company that develops first- or best-in-class targeted medicines for children and adults with life-threatening diseases, with a focus on cancers such as pediatric brain tumors. Founded in 2018, it received its first FDA approval in 2024 for a pediatric brain tumor treatment.

Companies working in the same space as Coultreon.

In the news

Coultreon Biopharma Raises $125 Million in Series A Financing to Advance Immunology Pipelinecoultreon.com · Apr 2026

Frequently asked questions

What does Coultreon do?: Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.
Who founded Coultreon?: Coultreon was founded by Pierre Raboisson, Marie De Vulder, Guy Peeters, John-Paul Gallivan, Fabrice Kolb, Pieter Peeters, François Gonzalvez, Sandrine Vendeville, Joost Kolkman in 2025.
Who are Coultreon's investors?: Coultreon's investors include Finchley Healthcare Ventures, Longwood Fund, Luma Group, Sofinnova Ventures, BAM Elevate, Forbion, Novo Holdings, Regeneron Ventures and 1 more.
How much funding has Coultreon raised?: Coultreon has disclosed $125M raised across 1 round.